.png){kind=icon}
.png){kind=icon}
Return
Belantamab mafodotin for patients with multiple myeloma: clinical development and practical strategies for dose optimization and toxicity management
.png){kind=icon}
PRE
AI
DOI：10.1016/j.clml.2026.06.014.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Belantamab mafodotin (belamaf) is an antibody–drug conjugate targeting B-cell maturation antigen on plasma cells. The phase III DREAMM-7 and DREAMM-8 trials, in which belamaf was combined with bortezomib–dexamethasone or pomalidomide–dexamethasone respectively, showed significantly higher overall response and measurable residual disease negativity rates for belamaf-combinations as compared to standard of care triplets, as well as improved longitudinal outcomes. Collectively, the results of DREAMM-7 and DREAMM-8 have established these regimens as a treatment option for patients with relapsed or refractory multiple myeloma, leading to regulatory approval of belamaf in combination with bortezomib by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA), and in combination with pomalidomide by the EMA.
Journal
IF:
2.7
Papers:
427
Citations:
4.2K
Organization
View more organizations